When Good Embryos Keep Not Implanting

What recurrent implantation failure actually means

Recurrent implantation failure describes repeated transfers of reasonable-quality embryos that do not lead to a pregnancy. The uncomfortable truth is that there is no universally agreed definition — clinics differ on how many embryos, how many transfers, or which embryo grades count — which is one reason the label can feel both frightening and vague. RIF is a description of a pattern, not a diagnosis with a single cause.

It is worth separating from a term it is often confused with. Recurrent implantation failure is about embryos that never implant; the workup after recurrent pregnancy loss deals with pregnancies that start — a positive test — and then end. The two overlap in emotional weight but point to different evaluations, and being on the right one saves time, money, and heartache.

Why it happens — the embryo is usually the main suspect

For most people, the single biggest driver of failed implantation is the embryo's chromosomes, not the uterus. A large share of human embryos carry the wrong number of chromosomes, and that share rises steeply with the egg provider's age — which is why a beautiful-looking embryo on the grading report can still fail to implant. Appearance and genetics are not the same thing.

This is also why simply testing the embryos is not the guaranteed fix it is sometimes sold as. Genetic testing for aneuploidy can help identify which embryos are chromosomally normal, but a large randomized trial and major professional guidance found that routine PGT-A did not raise live-birth rates across the general IVF population 1Ref 1Munné S, et al. (STAR Study Group) (2019).Preimplantation genetic testing for aneuploidy versus morphology as selection criteria for single frozen-thawed embryo transfer in good-prognosis patients: a multicenter randomized clinical trial.The STAR RCT found PGT-A did not improve ongoing-pregnancy rates versus morphology-based selection — evidence that routine PGT-A is not shown to raise live-birth rates for the general IVF population.2Ref 2Practice Committees of ASRM and SART (2024).The use of preimplantation genetic testing for aneuploidy: a committee opinion.The ASRM/SART position that the value of routine PGT-A has not been demonstrated and recent RCTs found similar pregnancy outcomes with or without it — the basis for cautioning against PGT-A as a guaranteed RIF fix.. It can reduce the number of transfers it takes to reach a normal embryo for some patients, but it does not manufacture a normal embryo where none exists. And a single ovarian-reserve test is not a verdict either — guidance is explicit that a low result does not by itself mean a person cannot conceive 3Ref 3Practice Committee of ASRM (2020).Testing and interpreting measures of ovarian reserve: a committee opinion.That a low ovarian-reserve result does not by itself mean a person cannot conceive — used to caution against over-reading a single test after failed transfers.. Holding both facts keeps expectations, and spending, grounded.

What a real RIF workup looks at

A focused evaluation after repeated failure looks at three things: the embryos, the uterus, and the transfer itself. On the uterine side, clinicians look for structural problems that genuinely lower implantation — polyps, fibroids that distort the cavity, scar tissue, a uterine septum, or a fluid-filled damaged fallopian tube (hydrosalpinx) that can wash back into the cavity. These are checked with imaging or a look inside the uterus, and several of them are correctable.

On the embryo side, the questions are quality, number, and — where appropriate — chromosomal testing. On the transfer side, the timing and technique are reviewed. A thorough workup is specific and testable; it is different from being handed a menu of expensive extras. If a proposed step cannot be tied to a plausible, evidence-based reason it would help your particular situation, that is worth noticing rather than accepting.

The add-ons to be skeptical of

Recurrent implantation failure is the point in IVF where unproven extras get sold hardest, because hope is high and 'we could try one more thing' is easy to say. The UK fertility regulator publishes a five-tier, color-coded rating of IVF add-ons, and many that are marketed for implantation failure — the ERA endometrial-receptivity test, endometrial scratching, assisted hatching, and various immune treatments — sit in the tiers with limited or no good evidence of benefit, some flagged for possible harm 4Ref 4Human Fertilisation and Embryology Authority (2024).Treatment add-ons with limited evidence.The UK regulator's five-tier rating in which many IVF add-ons, including several marketed for implantation failure such as the ERA and endometrial scratch, carry limited or no good evidence, with some flagged for possible harm.. Those weak-evidence add-ons deserve hard questions before any money changes hands.

Assessed honestly, the ERA test aims to personalize transfer timing, but the evidence that it lifts live-birth rates for most patients is thin 4Ref 4Human Fertilisation and Embryology Authority (2024).Treatment add-ons with limited evidence.The UK regulator's five-tier rating in which many IVF add-ons, including several marketed for implantation failure such as the ERA and endometrial scratch, carry limited or no good evidence, with some flagged for possible harm., so whether the era test is worth it is a fair thing to ask out loud. Immune therapies such as steroids and intralipid infusions are widely offered for this, and they carry their own risks. Even ICSI is not a default fix: guidance holds that, absent male-factor infertility or prior fertilization failure, routine ICSI does not improve live-birth rates 5Ref 5Practice Committees of ASRM and SART (2026).Intracytoplasmic sperm injection for nonmale factor indications: a committee opinion.That, absent male factor or prior fertilization failure, routine ICSI does not improve live-birth rates — used to caution against ICSI as a default response to implantation failure.. None of this means every add-on is useless for every person — it means the burden of proof belongs on the clinic recommending it. The regulator's add-on ratings and the professional societies' opinions are exactly the fertility clinic red flags to weigh against a sales pitch.

What actually tends to help

The measures with the best rationale are less dramatic than the add-ons. Correcting a genuine structural problem — removing a polyp, addressing a cavity-distorting fibroid, or treating a hydrosalpinx — targets a real, identifiable obstacle. Transferring chromosomally normal embryos, where testing is appropriate, addresses the most common cause. And building a larger bank of embryos over more than one retrieval gives more chances at a normal embryo, especially as the egg provider's age works against the odds.

One thing that usually does not help is transferring more embryos at once out of frustration. Guidance supports elective single-embryo transfer because moving one good embryo keeps pregnancy rates comparable while sharply lowering the risk of twins and their complications 6Ref 6Practice Committees of ASRM and SART (2021).Guidance on the limits to the number of embryos to transfer: a committee opinion.That transferring a single embryo keeps pregnancy rates comparable while sharply lowering twin risk — the basis for not escalating to multiple embryos out of frustration after RIF. — piling on embryos tends to raise the danger without fixing the underlying reason for failure. Patience with a sound plan, hard as it is, generally beats escalation for its own sake.

Getting a second opinion and what to ask

Because recurrent implantation failure is where sales pressure peaks, a second opinion is often worth the trouble — ideally from a clinic that does not benefit from selling you the next add-on. The goal is not to distrust everyone; it is to make each proposed step justify itself before you pay for it.

• For each recommended add-on: what is the evidence it improves live births for someone like me?
• Has my uterus been properly evaluated for polyps, fibroids, scarring, or a hydrosalpinx?
• Would genetic testing of embryos change the plan, and why or why not?
• What is the ivf all-in cost of the proposed plan, and which parts are ivf price add-ons?
• Are we escalating for a reason, or out of understandable frustration?

Reading proposed extras against the regulator's HFEA add-on ratings and the ASRM add-ons opinion turns a sales conversation into an evidence conversation — which is where the decision belongs.